Zobrazeno 1 - 10
of 20
pro vyhledávání: '"K. Sue Robinson"'
Autor:
Haowei (Linda) Sun, Ming Yang, Man‐Chiu Poon, Adrienne Lee, K. Sue Robinson, Michelle Sholzberg, John Wu, Alfonso Iorio, Victor Blanchette, Manuel Carcao, Robert J. Klaassen, Shannon Jackson
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021)
Abstract Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Cana
Externí odkaz:
https://doaj.org/article/cdf7d3770049495c886f6d00d200190b
Autor:
K Sue Robinson, Adrienne Lee, Manuel Carcao, Alfonso Iorio, Ming Yang, Michelle Sholzberg, Victor S. Blanchette, Robert J. Klaassen, John K. Wu, Man-Chiu Poon, Haowei Linda Sun, Shannon Jackson
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis
Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian pers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a03ab07ff90bdb767212e2ad5d8c68
https://doaj.org/article/cdf7d3770049495c886f6d00d200190b
https://doaj.org/article/cdf7d3770049495c886f6d00d200190b
Autor:
K. Sue Robinson
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 58(5)
Factor VII (FVII) deficiency is the most common of the Rare Inherited Coagulation Disorders. The inheritance is autosomal recessive but there is variable penetrance. Overall there is poor correlation between the FVII level and the bleeding phenotype.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58057e5d6e47acb5a922287eb1905374
https://pubmed.ncbi.nlm.nih.gov/31447397
https://pubmed.ncbi.nlm.nih.gov/31447397
Autor:
Jonathan W. Friedberg, Richard I. Fisher, Ranjana H. Advani, Randy D. Gascoyne, K. Sue Robinson, Kristie A. Blum, Richard T. Hoppe, Douglas A. Stewart, Nancy L. Bartlett, Brad S. Kahl, Patrick J. Stiff, Sandra J. Horning, Thomas M. Habermann, Bruce D. Cheson, Henry N. Wagner, Leo I. Gordon, Joseph Tuscano, Fangxin Hong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 33, iss 17
Purpose The phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechloreth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf5c90bef712ea6e22931dc25dbb522
https://doi.org/10.1200/jco.2014.57.8138
https://doi.org/10.1200/jco.2014.57.8138
Autor:
Keith Stewart, K. Sue Robinson, David P. Sheridan, George A. Wells, Andrew Belch, Richard van der Jagt, Chaim Shustik, Stefan Glück, Elizabeth Yetisir, Loree Larratt
Publikováno v:
Leukemia & Lymphoma. 47:697-706
The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML). The combinations of idarubicin 12 mg/m(2)/d on days 1 - 3 and Ara-C (200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b01e24bda45f5ca2b03cd2871aaf812
https://doi.org/10.1080/10428190500467917
https://doi.org/10.1080/10428190500467917
Autor:
David Alexander, Bruce Flemming, Ross Leighton, David Petrie, Michael Mitchell, David Anderson, Michael Gent, William D. Stanish, K Sue Robinson, Michael Gross
Publikováno v:
Chest. 114:119S-122S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0786baa1e94a660d20fc22d871b850e9
https://doi.org/10.1378/chest.114.2_supplement.119s
https://doi.org/10.1378/chest.114.2_supplement.119s
Autor:
Ling Chen, John P. Leonard, Robin Joyce, Myron S. Czuczman, K. Sue Robinson, Bruce D. Cheson, Brad S. Kahl, Michael E. Williams, Richard van der Jagt, Nancy L. Bartlett, Kristen N. Ganjoo
Publikováno v:
Cancer.
Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma.Eligible patients (N = 100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::347c51ac2f4aa37e3f2d8c9bf19ac78f
https://doi.org/10.1002/cncr.24714
https://doi.org/10.1002/cncr.24714
Autor:
Philip R. Cohen, K. Sue Robinson, Lee S. Schwartzberg, Michael E. Williams, Bruce D. Cheson, Jordan A. Herst, Anil Tulpule, Bernard Lemieux, Richard van der Jagt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(27)
Purpose Bendamustine HCl is a bifunctional mechlorethamine derivative with clinical activity in the treatment of non-Hodgkin's lymphoma. This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb45b114cd990c613aeb9f48852476b
https://pubmed.ncbi.nlm.nih.gov/18626004
https://pubmed.ncbi.nlm.nih.gov/18626004
Autor:
Michael E. Williams, Alberto Bessudo, Elber S. Camacho, Luis Fayad, Ling Chen, Andres Forero-Torres, Bruce D. Cheson, Ann S. La Casce, Richard van der Jagt, Jennifer Oliver, Philip Cohen, K. Sue Robinson, Jonathan W. Friedberg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2)
Purpose Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituxima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ab6aa21c75187c36646d50b8c9559b
https://pubmed.ncbi.nlm.nih.gov/18182663
https://pubmed.ncbi.nlm.nih.gov/18182663
Publikováno v:
Canadian Urological Association Journal. 9:905
Acquired hemophilia A is a rare condition caused by spontaneous development of factor VIII inhibitor. This condition most commonly presents with multiple hemorrhagic symptoms and isolated hematuria is exceedingly rare. Early diagnosis is important, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3738354c1d328183915569a6c58e51
https://doi.org/10.5489/cuaj.3306
https://doi.org/10.5489/cuaj.3306